# Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

> **NCT00612638** · PHASE1 · COMPLETED · sponsor: **Duke University** · enrollment: 96 (estimated)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** Temodar, O6-BG, and Irinotecan

## Key facts

- **NCT ID:** NCT00612638
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-01
- **Final completion:** 2008-07
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2013-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612638, "Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00612638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*